Kuick Research has announced the groundbreaking initiation of the world's first mRNA lung cancer vaccine trials, collaborating with the German biotech firm BioNTech SE (BNTX) on their promising candidate, BNT116. This marks a significant advancement in cancer treatment.
Neeraj Chawla, the Research Head at Kuick Research, revealed that over 60 mRNA cancer vaccines are currently in clinical trials. The first commercially approved mRNA cancer vaccine is anticipated to be market-ready by 2029.
BioNTech's BNT116 is tailored to combat non-small cell lung cancer (NSCLC), representing a crucial stride in the realm of personalized medicine. Utilizing messenger RNA (mRNA) technology, similar to that in COVID-19 vaccines, BNT116 aims to prompt the immune system to target cancer cells instead of a virus.
As the trial progresses, researchers strive to demonstrate BNT116's efficacy in preventing the recurrence of lung cancer. Positive outcomes from these trials could pave the way for mRNA cancer vaccines to become a standard treatment option globally.
The BNT116 clinical trial, spanning seven countries, will involve approximately 130 patients with various stages of lung cancer, from early to advanced or recurrent cases. These participants will receive the vaccine in combination with immunotherapy to enhance therapeutic results.
Kuick Research highlighted that over five mRNA-based lung cancer vaccines are currently in clinical trials. Globally, more than 20 mRNA cancer vaccines are undergoing clinical trials, with the U.S. and China leading the research and development efforts.
